Drug Overview

Pulrodemstat (also known as CC-90011) is an innovative cancer medication designed to treat specific types of advanced tumors. It is a prime example of a Targeted Therapy or “Smart Drug.” Unlike traditional chemotherapy that attacks all fast-growing cells, pulrodemstat is engineered to target the internal “instruction manual” of a cancer cell.

This medication works by focusing on epigenetics, the study of how cells turn certain genes on or off. In many cancers, the “off switch” for tumor-suppressing genes is stuck in the wrong position. Pulrodemstat acts like a biological technician, helping to reset these switches so the body can naturally stop cancer growth. It is currently being utilized in high-level clinical research across international oncology centers.

Generic Name: Pulrodemstat
US Brand Names: None (Currently an investigational drug)
Drug Class: Lysine-Specific Demethylase 1 (LSD1) Inhibitor
Route of Administration: Oral (Tablet/Capsule)
FDA Approval Status: Investigational (Currently in Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how pulrodemstat works, imagine a cancer cell is a library. In a healthy cell, the books (genes) that tell the cell to stop growing are easy to read. In cancer, a protein called LSD1 acts like a person who glues the pages of those specific books together so they cannot be read.

At the molecular level, pulrodemstat functions through a process called Epigenetic Modification:

LSD1 Inhibition: Pulrodemstat binds to the active site of the Lysine-Specific Demethylase 1 (LSD1) enzyme. LSD1 is responsible for removing “methyl groups” (chemical tags) from proteins called histones.
Histone Resetting: When LSD1 is blocked by pulrodemstat, the methyl groups stay on the histones (specifically H3K4 and H3K9). This keeps the DNA structure “open.”
Gene Re-activation: Because the DNA is open, the cell can finally “read” its tumor-suppressor genes again. These genes send signals that tell the cancer cell to stop dividing or to undergo apoptosis (programmed cell death).
Differentiation: In some blood cancers, LSD1 prevents immature cancer cells from “growing up” into normal, functioning blood cells. Pulrodemstat forces these cells to differentiate, effectively turning a “malignant” cell into a “mature” cell that eventually dies naturally.

FDA-Approved Clinical Indications

As an investigational drug, pulrodemstat is not yet approved for general use. It is currently available to patients through strictly monitored clinical trials.

Oncological Uses (Investigational)

Small Cell Lung Cancer (SCLC): For patients whose cancer has returned after initial chemotherapy.
Neuroendocrine Tumors (NETs): Specifically, advanced or metastatic cases.
Acute Myeloid Leukemia (AML): Investigated for use in combination with other agents.
Myelofibrosis: Chronic bone marrow disorders.

Non-Oncological Uses

There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Pulrodemstat is taken by mouth, which allows for convenient at-home treatment under a physician’s guidance.

Protocol Detail	Standard Investigational Guidance
Typical Dose	10 mg to 120 mg (dose-escalation studies)
Frequency	Once daily or on specific weekly cycles (e.g., 4 days on, 3 days off)
Administration	Oral; usually taken at the same time each day
Cycle Length	Continued until disease progression or unacceptable toxicity

Dose Adjustments:

Hepatic/Renal Insufficiency: Because this drug is still in testing, standard dose adjustments for liver or kidney issues are not yet established. Patients with these conditions are monitored closely for changes in blood chemistry.

Clinical Efficacy and Research Results

Recent clinical data from 2020–2025 (including Phase I/II trials) have shown promising results in hard-to-treat “cold” tumors.

Disease Control: In trials for neuroendocrine tumors and small cell lung cancer, pulrodemstat has demonstrated a Disease Control Rate (DCR) of approximately 40-50% in specific patient groups.
Progression-Free Survival: Numerical data indicate that some patients with previously progressing neuroendocrine tumors maintained “stable disease” for over 6 months while on therapy.
SCLC Response: In combination with chemotherapy, early results suggest pulrodemstat may help sensitize cancer cells that were previously resistant to treatment, though overall survival data is still being gathered.

Safety Profile and Side Effects

Pulrodemstat has a unique safety profile. Because it affects how blood cells are made, it requires regular monitoring of blood counts.

Black Box Warning:

None. (Investigational drugs do not receive formal Black Box Warnings).

Common Side Effects (>10%)

Thrombocytopenia: A drop in blood platelets, which may cause easier bruising.
Fatigue: Feeling unusually tired or weak.
Nausea: General stomach upset (usually mild).
Decreased Appetite: Leading to minor weight loss.
Anemia: Low red blood cell counts.

Serious Adverse Events

Severe Myelosuppression: A significant drop in all blood cell types, increasing the risk of bleeding or infection.
Gastrointestinal Bleeding: Linked to very low platelet counts.

Management Strategies

Dose Holds: If platelet counts fall too low, the doctor will pause treatment for a week to allow the bone marrow to recover.
Supportive Care: Use of anti-nausea medications and, in some cases, blood or platelet transfusions.

Research Areas

Pulrodemstat is currently a major focus in Immunotherapy research. Scientists are exploring if LSD1 inhibitors like pulrodemstat can turn “cold” tumors (cancers that the immune system ignores) into “hot” tumors. By changing the cell’s genetic switch, the drug may make cancer cells “visible” to the immune system. Current research is also looking at how this drug interacts with Hematopoietic Stem Cells to ensure that while it kills cancer, it allows healthy stem cells to keep producing healthy blood.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Complete Blood Count (CBC): To check baseline levels of white cells, red cells, and platelets.
Biomarker Testing: Some trials check for high LSD1 levels in the tumor tissue.
Liver and Kidney Function (CMP).

Precautions During Treatment

Monitor for Bleeding: Patients should watch for tiny red spots on the skin (petechiae), nosebleeds, or bleeding gums.
Infection Control: Wash hands frequently and avoid people who are sick, as your white blood cell count may fluctuate.

“Do’s and Don’ts” List

Do take the medication at the same time every day to keep levels steady.
Do report any unusual bruising or black/tarry stools immediately.
Don’t take new herbal supplements without asking your oncology team, as they can interfere with liver enzymes.
Don’t assume a mild fever is normal; report any temperature over 100.4°F (38°C).

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Pulrodemstat is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional regarding your specific diagnosis and treatment plan. This content reflects clinical data available as of 2026.